{"id":82566,"date":"2026-07-08T12:05:11","date_gmt":"2026-07-08T12:05:11","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/"},"modified":"2026-07-08T12:05:11","modified_gmt":"2026-07-08T12:05:11","slug":"60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/","title":{"rendered":"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases"},"content":{"rendered":"<div>\n<ul>\n<li><strong>License <\/strong><strong>expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease<\/strong><\/li>\n<li><strong>Agreement builds on Company&#8217;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis<\/strong><\/li>\n<li><strong>Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development<\/strong><\/li>\n<\/ul>\n<p>WASHINGTON, July  08, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gpEOgUoUVFaIEMu9RVUyKTamAtsdF_GXxj75aabb6qD-U32z4cWmzulkIlqthH-MMokqTa3X6qM5vd2qmBzvtaCvbG0RZ91BggYu1_t1_gM6cFKu4hvhQVdK4tLGWhaHwi8LgzlOs6zXoP-mC_t0qQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>60 Degrees Pharmaceuticals, Inc.<\/u><\/a>\u00a0(NASDAQ: SXTP; SXTPW) (the \u201cCompany\u201d or \u201c60\u00a0Degrees Pharma\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it has entered into an exclusive option agreement with the Florida State University Research Foundation (FSURF) covering intellectual property related to the therapeutic development of castanospermine for multiple tick-borne diseases.<\/p>\n<p>Under the agreement, 60 Degrees Pharma has an exclusive option to negotiate an exclusive U.S. license for patented technology and associated know-how relating to the use of castanospermine in the fields of Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. The agreement also provides the Company with an evaluation period to develop a commercialization strategy and supporting development plan.<\/p>\n<p>Castanospermine is a naturally occurring iminosugar found in Australian Chestnut (<em>Castanospermum australe<\/em>). The compound has demonstrated broad antiviral and immunomodulatory activity in preclinical studies. There is substantial human safety experience from clinical trials with celgosivir, a pro-drug that converts almost completely to castanospermine after oral administration.<\/p>\n<p>\u201cThis agreement reflects our belief that castanospermine may have its greatest long-term value as the basis for innovative prescription medicines addressing important unmet needs in tick-borne diseases,\u201d said Geoff Dow, Chief Executive Officer of 60 Degrees Pharma. \u201cThe option agreement gives us the flexibility to advance a focused development strategy while leveraging our existing expertise in vector-borne infectious diseases.\u201d<\/p>\n<p>The Company recently met with the U.S. Food and Drug Administration to discuss its New Dietary Ingredient Notification for use of Australian Chestnut Extract in a dietary supplement. Following those discussions, the Company is re-evaluating its regulatory strategy for the dietary supplement opportunity while prioritizing development programs where castanospermine may provide greater clinical and commercial value.<\/p>\n<p><strong>About\u00a060 Degrees Pharmaceuticals, Inc.<\/strong><br \/>60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved\u00a0U.S. Food and Drug Administration\u00a0approval of its lead product, ARAKODA\u00ae (<strong>tafenoquine<\/strong>), for malaria prevention in 2018. ARAKODA is commercially available in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0also collaborates with prominent research and academic organizations in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0is headquartered in\u00a0Washington, D.C., with a subsidiary in\u00a0Australia. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E6-eSfLXzksAA1OICpXz2yMryYCccL-_KBdphUhjNahGsfRb_ge9bSDeOPeOntUmoamFimqmb0aXQYBvolwbCf666K3fu3FPMheHzh6vT5HHHmYz8RhYd7me85WKUUmR\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.60degreespharma.com<\/u><\/a>.<\/p>\n<p>The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management\u2019s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.<\/p>\n<p><strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>This press release may contain \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cplan,\u201d or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,\u00a0expectations\u00a0and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for\u00a0<strong>tafenoquine<\/strong>\u00a0(ARAKODA<sup>\u00ae<\/sup>\u00a0or other regimen) or Australian Chestnut Extract in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market.\u00a0More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d), including the information contained in our Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0March 30, 2026, and our subsequent\u00a0SEC\u00a0filings. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at\u00a0www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company\u2019s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>Media Contact<br \/>Kristen Landon<br \/>kristenlandon@60degreespharma.com<\/p>\n<p>Investor Contact<br \/>Patrick Gaynes<br \/>patrickgaynes@60degreespharma.com<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODk1YTJiOTktOTM0YS00NGI2LTlhNmQtNGY3Y2Q0OGQ2OTAyLTExOTM5MDctMjAyNi0wNy0wOC1lbg==\/tiny\/Sixty-Degrees-Pharmaceuticals.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease Agreement builds on Company&#8217;s expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development WASHINGTON, July 08, [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-82566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases\" \/>\n<meta property=\"og:description\" content=\"License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T12:05:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases\",\"datePublished\":\"2026-07-08T12:05:11+00:00\",\"dateModified\":\"2026-07-08T12:05:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\"},\"wordCount\":1007,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"People\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\",\"name\":\"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-07-08T12:05:11+00:00\",\"dateModified\":\"2026-07-08T12:05:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/","og_locale":"en_US","og_type":"article","og_title":"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases","og_description":"License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal","og_url":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-07-08T12:05:11+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases","datePublished":"2026-07-08T12:05:11+00:00","dateModified":"2026-07-08T12:05:11+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/"},"wordCount":1007,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["People"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/","url":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/","name":"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-07-08T12:05:11+00:00","dateModified":"2026-07-08T12:05:11+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/82566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=82566"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/82566\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=82566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=82566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=82566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}